Arbor Biotechnologies Announces FDA Acceptance of IND Application for ABO-101 for the Treatment of Primary Hyperoxaluria Type 1
December 20, 2024
December 20, 2024
CAMBRIDGE, Massachusetts, Dec. 20 -- Arbor Biotechnologies, a biotechnology company that says it discovers and develops genetic medicines, issued the following news release on Dec. 19, 2024:
* * *
RedePHine phase 1/2 clinical trial initiation expected in first half of 2025
* * *
Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that the U.S. Food and Drug Administ . . .
* * *
RedePHine phase 1/2 clinical trial initiation expected in first half of 2025
* * *
Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that the U.S. Food and Drug Administ . . .